Last November, the FDA released an Emergency Use Authorization (EUA) for the use of monoclonal antibody therapy for adult and pediatric patients with mild to moderate COVID-19. Currently, there is some confusion about the availability and access issues to these treatment options.
In this episode, part two of a three-part series, we will address questions and concerns about the distribution and availability of these therapies.
Guest speakers:Azra Behlim, PharmD, MBASenior DirectorPharmacy Sourcing and Program Services Vizient
Steve Rud...
Last November, the FDA released an Emergency Use Authorization (EUA) for the use of monoclonal antibody therapy for adult and pediatric patients with mild to moderate COVID-19. Currently, there is some confusion about the availability and access issues to these treatment options.
In this episode, part two of a three-part series, we will address questions and concerns about the distribution and availability of these therapies.
Guest speakers:
Azra Behlim, PharmD, MBA
Senior Director
Pharmacy Sourcing and Program Services
Vizient
Steve Rudner, PharmD, MS
Director
Pharmacy Network Contracting
Vizient
Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Associate Vice President
Clinical Resources
Vizient
Show Notes:
[02:05] Access to the monoclonal antibody therapies
[03:51] No lack of supply
[05:07] Infusion options
[09:59] Misconceptions and challenges around distribution
[11:40] Every idea worth exploring
Links | Resources:
Press release and information from FDA Click here
Information from FDA on EUA for monoclonal antibody therapy Click here
ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here
[ For more information, contact: ASPRstakeholder@HHS.gov ]
JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here
Subscribe Today!
Apple Podcasts
Spotify
Android
Google Podcasts
Stitcher
RSS Feed
View more
